These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615 [Abstract] [Full Text] [Related]
4. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768 [Abstract] [Full Text] [Related]
5. Halofuginone: a novel antifibrotic therapy. Pines M, Nagler A. Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159 [Abstract] [Full Text] [Related]
7. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Pines M, Domb A, Ohana M, Inbar J, Genina O, Alexiev R, Nagler A. Biochem Pharmacol; 2001 Nov 01; 62(9):1221-7. PubMed ID: 11705455 [Abstract] [Full Text] [Related]
8. Growth inhibition of prostate cancer xenografts by halofuginone. Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, Pines M. Prostate; 2002 May 01; 51(2):73-83. PubMed ID: 11948962 [Abstract] [Full Text] [Related]
10. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Neoplasia; 1999 Oct 01; 1(4):321-9. PubMed ID: 10935487 [Abstract] [Full Text] [Related]
13. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA. Arthritis Rheum; 2002 Oct 01; 46(10):2748-61. PubMed ID: 12384935 [Abstract] [Full Text] [Related]
14. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. Hepatology; 2001 Feb 01; 33(2):379-86. PubMed ID: 11172339 [Abstract] [Full Text] [Related]
15. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M. Pancreas; 2009 May 01; 38(4):427-35. PubMed ID: 19188864 [Abstract] [Full Text] [Related]
17. Halofuginone: an inhibitor of collagen type I synthesis. Granot I, Halevy O, Hurwitz S, Pines M. Biochim Biophys Acta; 1993 Feb 13; 1156(2):107-12. PubMed ID: 8427869 [Abstract] [Full Text] [Related]
20. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury. Ozçelik MF, Pekmezci S, Saribeyoğlu K, Unal E, Gümüştaş K, Doğusoy G. Am J Surg; 2004 Feb 13; 187(2):257-60. PubMed ID: 14769315 [Abstract] [Full Text] [Related] Page: [Next] [New Search]